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Sequence variants of the Epstein–Barr virus (EBV)-encoded latent membrane protein-1 (LMP1) have been reported in
association with EBV-linked malignancies but little is known about their effects on signalling pathways and phenotype. We
have examined the ability of the nasopharyngeal carcinoma (NPC)-derived variant, CAO-LMP1 to activate the transcription
factors NF-kB and AP-1 in epithelial cells. In this study, transient expression of CAO-LMP1 was found to activate higher levels
of NF-kB and AP-1 than the prototype B95.8-LMP1 in human embryonic kidney (HEK) 293 cells and SV40-transformed
keratinocytes (SVK). In addition, pulse–chase analysis revealed that CAO-LMP1 has a longer half-life than B95.8-LMP1.
Chimera studies localised these phenomena to the transmembrane domains of CAO-LMP1, suggesting that this enhanced
signalling capacity may be a consequence of its prolonged half-life. The ability of CAO-LMP1 to activate higher levels of
NF-kB and AP-1 may contribute to its potent transforming properties. © 2001 Academic PressKey Words: LMP1; CAO; NF-kB; AP-1.
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1INTRODUCTION
Epstein–Barr virus (EBV), a gamma herpes virus, is
associated with a number of malignancies, including
Burkitt’s lymphoma, nasopharyngeal carcinoma (NPC),
and Hodgkin’s disease (Rickinson and Kieff, 1996). A
subset of viral genes is expressed when EBV transforms
resting B lymphocytes into lymphoblastoid cell lines
(LCLs), including latent membrane protein-1 (LMP1).
LMP1 is a 63-kDa integral membrane protein, consisting
of a short highly charged cytoplasmic amino terminus of
23 aa, 6 hydrophobic transmembrane domains required
for protein aggregation, and a long acidic cytoplasmic
carboxyl-terminus of 200 aa (Fennewald et al., 1984). The
carboxyl-terminus comprises two functional domains:
the membrane proximal CTAR1 (residues 194–232 also
referred to as TES1) and the membrane distal CTAR2
(residues 351–386 also referred to as TES2) (Huen et al.,
1995) through which LMP1 activates several signalling
pathways.
Compelling evidence for the importance of LMP1 in B
cell transformation was provided by EBV recombinant
genetic analysis in which recombinant EBV expressing
mutated LMP1 was non-transforming (Kaye et al., 1993).
The amino terminus, transmembrane domains and
CTAR1 are critical for this process (Izumi et al., 1997)
whilst CTAR2 is required for long-term outgrowth of the
transformed B cells (Izumi and Kieff, 1997; Kaye et al.,
1995). The residues between CTAR1 and CTAR2 (aa
232–351) are dispensable for initial B cell transformation
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278and maintenance of long-term outgrowth (Izumi et al.,
1999). In addition, LMP1 has the ability to growth trans-
form rodent fibroblasts in culture and is thus considered
an oncogene (Wang et al., 1985).
In B cells, in the absence of other EBV gene products,
LMP1 expression results in upregulation of the cell sur-
face markers, CD21, CD23, CD39, CD40, CD54, LFA-1,
and LFA-3 (Wang et al., 1988, 1990), and also protects
these cells from apoptosis by the induction of bcl-2
(Henderson et al., 1991), Mcl-1 (Wang et al., 1996) and
A20 (Laherty et al., 1992). In epithelial cells, LMP1 up-
regulates CD40, CD54, and A20 expression (Huen et al.,
1995; Miller et al., 1997) and inhibits differentiation (Daw-
son et al., 1990) and cell growth (Eliopoulos et al., 1996;
Hammerschmidt et al., 1989; Kaykas and Sugden, 2000).
The membrane-proximal CTAR1 domain contains a
PxQxT motif (residues 204–208) similar to that found in
CD40 and TNF-R2, and it is through this motif that CTAR1
binds TRAFs 1, 2, 3, and 5 (Brodeur et al., 1997; Mosialos
et al., 1995; Devergne et al., 1996; Sandberg et al., 1997).
CTAR2 was identified as the major NF-kB activation
omain (Huen et al., 1995; Mitchell and Sudgen, 1995)
nd this NF-kB activation mapped to the far C terminus,
residues 379–384 (Floettmann and Rowe, 1997). Al-
though CTAR2 is unable to bind TRAFs directly, a domi-
nant negative TRAF2 molecule partially inhibits CTAR2-
mediated NF-kB activation, suggesting it may interact
ndirectly (Eliopoulos et al., 1997; Kaye et al., 1996).
TAR2 is able to bind the TNF receptor-associated death
omain protein (TRADD), which augments NF-kB activa-
ion by LMP1 (Eliopoulos et al., 1999a; Izumi and Kieff,
997). Downstream of TRAF2, NF-kB activation from bothCTAR domains is mediated through NF-kB-inducing ki-
d
a
i
A
1
f
a
c
c
a
1
q
t
i
t
s
s
C
i
a
L
c
w
p
279ENHANCED SIGNALLING FROM CAO-LMP1nase (NIK) (Eliopoulos et al., 1999a; Sylla et al., 1998).
Other signalling pathways activated by LMP1 include the
c-Jun amino terminal kinase (JNK) pathway. LMP1-in-
duced JNK activation is mediated entirely by CTAR2 (Elio-
poulos and Young, 1998; Kieser et al., 1997) and involves
both TRADD and TRAF2 (Eliopoulos et al., 1999a; Elio-
poulos and Young, 1998). LMP1 also activates the extra-
cellular signal regulated kinase (ERK) pathway in a ras-
dependent manner (Roberts and Cooper, 1998), the p38
MAPK cascade via both CTAR1 and CTAR2 (Eliopoulos et
al., 1999b) and JAK3 resulting in the activation of the
STAT1 transcription factor, which was maps to the repeat
region of LMP1 (Gires et al., 1999).
LMP1 is similar to growth factor receptors in that it is
turned over rapidly. Pulse–chase analysis has shown
that it has a half-life of between 2 and 5 h, depending on
the cell type (Baichwal and Sugden, 1987; Mann and
Thorley-Lawson, 1987; Moorthy and Thorley-Lawson,
1990). Recent work has identified amino terminal ubiq-
uitination followed by proteasomal degradation as the
mechanism by which LMP1 is turned over (Aviel et al.,
2000).
LMP1 sequence variants have been reported in asso-
ciation with EBV-linked malignancies including NPC. The
CAO-LMP1 variant was cloned from the genomic library
of a nude mouse-propagated Chinese NPC and, com-
pared to B95.8-LMP1, has nucleotide substitutions lo-
cated mostly in the amino terminus and transmembrane
domains, three additional 33-bp repeats in the cytoplas-
mic carboxyl-terminus, and a 30-bp deletion proximal to
the start of CTAR2 (Hu et al., 1991). This LMP1 variant is
more tumourigenic than prototype B95.8-LMP1 in kera-
tinocytes (Hu et al., 1993) and less immunogenic (Trivedi
et al., 1994). Analysis of LMP1-activated signalling path-
ways in lymphoid cell lines found that CAO-LMP1 acti-
vated higher levels of NF-kB than B95.8-LMP1 but para-
doxically was impaired in its ability to upregulate pheno-
typic markers (Johnson et al., 1998). This study
emonstrates that CAO-LMP1 confers enhanced NF-kB
nd AP-1 signalling in epithelial cells and implicates
ncreased protein stability in these phenomena.
RESULTS
nalysis of B95.8 and CAO-LMP1 sequence
DNA sequencing of pSG5 B95.8-LMP1 (Huen et al.,
995) and pSG5 CAO-LMP1 (Johnson et al., 1998) con-
irmed the published sequences for B95.8-LMP1 (Baer et
l., 1984) but not for CAO-LMP1 (Hu et al., 1991). In
ontrast to the published sequence (Hu et al., 1991),
hanges were not found at amino acids 7, 8, 11, 12, in
greement with a recent study (Johnson et al., 1998), and
20, which were identical to those of the B95.8 se-
uence. Two additional changes were found, one in the
ransmembrane domains at amino acid 122, a leucine
nstead of isoleucine, and the other in the carboxyl-
erminus at amino acid 337, an asparagine instead oferine. A schematic representation of these molecules is
hown in Fig. 1.
AO-LMP1 activates higher levels of NF-kB and AP-1
than B95.8-LMP1
The effect of CAO-LMP1 on cellular signalling path-
ways has been studied transiently in lymphoid cells and
in stably expressing epithelial cells with interesting re-
sults. In transiently transfected lymphoid cells, CAO-
LMP1 activates higher levels of NF-kB but is impaired in
ts ability to upregulate cell surface markers (Johnson et
l., 1998). In stably expressing epithelial cells, CAO-
MP1 activates comparable levels of NF-kB to B95.8 but
is impaired in its ability to activate AP-1 and cell surface
markers (Dawson et al., 2000). To examine the transient
effects of B95.8 and CAO-LMP1 on NF-kB in epithelial
ells, HEK 293 and SVK cells were transiently transfected
ith 5 mg pSG5 or pSG5-based LMP1 constructs in the
resence of a NF-kB luciferase reporter plasmid. Thirty-
six hours posttransfection, cells were harvested and
lysates analysed for LMP1 expression by immunoblot-
ting with the CS.1–4 monoclonal antibodies (Rowe et al.,
FIG. 1. Schematic representation of prototype B95.8 and NPC-de-
rived CAO-LMP1. Schematic representation of B95.8 and CAO-LMP1.
The cytoplasmic carboxyl-terminus comprises two functional domains,
known as C-terminal activating region 1 (CTAR1, aa 194–232) and
CTAR2 (aa 351–386). The region linking CTAR1 and CTAR2 contains
several repeating motifs. The amino acids in CAO-LMP1 that were
found to differ from B95.8-LMP1 are denoted by black circles and their
position shown. CAO-LMP1 also contains three additional repeats and
a 10 aa deletion in the cytoplasmic carboxyl-terminus compared to
B95.8-LMP1.1987), and NF-kB activity by reporter and electrophoretic
L
r
w
E
C
e
o
i
a
A
w
a
i
s
p
w
i
I
i
t
e
m
w
280 BLAKE ET AL.mobility shift assays (EMSAs). Figure 2A shows repre-
sentative immunoblots, which verify that CAO-LMP1 has
FIG. 2. NF-kB activation by the LMP1 variants B95.8 and CAO. HEK
293 and SVK cells were transfected with 5 mg pSG5 or pSG5-based
LMP1 constructs in the presence of a NF-kB luciferase reporter plas-
mid (kBconA-Luc) and equivalent amounts of a b-galactosidase ex-
ression vector (CMV-b-gal). Thirty-six hours posttransfection, cells
ere harvested and samples were analysed for LMP1 expression by
mmunoblotting and NF-kB activity by reporter assay and EMSA. (A)
mmunoblot of a representative experiment showing LMP1 expression
n transiently transfected HEK 293 cells (left) and SVK cells (right) using
he CS.1–4 monoclonal antibodies. (B) NF-kB binding assay in 293 cells
(left) and SVK cells (right) transiently transfected with 5 mg pSG5 or
pSG5-based LMP1 constructs. Thirty-six hours posttransfection, nu-
clear extracts were isolated and examined for NF-kB binding activity
using a 32P-labeled HIV-kB probe in EMSAs. (C) NF-kB reporter assay
in 293 and SVK cells transfected with 5 mg pSG5 or pSG5-based LMP1
constructs in the presence of kBconA-Luc and CMV-b-gal. Relative
luciferase values [RLV (NF-kB)] were calculated as the ratio of lucif-
rase versus b-galactosidase activity and results are depicted as
eans 6 standard deviation of four independent experiments. RLV
ere compared using the Student’s t test: a/b P , 0.01, c/d P , 0.05.a higher molecular weight than B95.8-LMP1, and showsCAO-LMP1 is expressed at marginally higher levels in
both cell lines. Interestingly, CAO-LMP1 was found to
induce higher levels of NF-kB binding by EMSA (Fig. 2B)
and significantly higher levels of NF-kB activation by
luciferase reporter assay (Fig. 2C) in both HEK 293 and
SVK cells. To compare the effects of B95.8 and CAO-
LMP1 on AP-1 in epithelial cells, HEK 293 cultures were
transiently transfected with 5 mg pSG5 or pSG5-based
MP1 constructs in the presence of an AP-1 luciferase
eporter plasmid. Thirty-six hours posttransfection, cells
ere harvested and lysates analysed for AP-1 activity by
MSA and reporter assay. Compared with B95.8-LMP1,
AO-LMP1 was consistently found to induce higher lev-
ls of AP-1 binding by EMSA (Fig. 3A) and higher levels
f AP-1 activation by luciferase reporter assays (Fig. 3B)
FIG. 3. AP-1 activation by the LMP1 variants B95.8 and CAO. HEK 293
cells were transfected with 5mg pSG5 or pSG5-based LMP1 constructs
n the presence of an AP-1 luciferase reporter plasmid and equivalent
mounts of CMV-b-gal. Thirty-six hours posttransfection, cells were
harvested and samples were analysed for AP-1 activity by reporter
assay and EMSA. (A) AP-1 reporter assay in HEK 293 cells transfected
with 5 mg pSG5 or pSG5-based LMP1 constructs in the presence of
P-1 reporter and CMV-b-gal. Relative luciferase values [RLV (AP-1)]
ere calculated as the ratio of luciferase vs b-galactosidase activity,
nd results are depicted as mean 6 standard deviation of three
ndependent experiments. (B) AP-1 binding assay in 293 cells tran-
iently transfected with 5 mg pSG5 or pSG5-based LMP1 constructs.
Thirty-six hours posttransfection, nuclear extracts were isolated and
examined for AP-1 binding activity using a 32P-labeled collagenase TRE
probe in EMSAs.
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281ENHANCED SIGNALLING FROM CAO-LMP1in HEK 293 cells although the difference was not statis-
tically significant.
Enhanced NF-kB activation by CAO-LMP1 localises to
he transmembrane domains
To map the domain of CAO-LMP1 responsible for
nhanced signalling activity, a series of chimeras were
onstructed that are schematically represented in Fig.
A. Generation of chimeric molecules rather than dele-
ion mutants was chosen since large deletions may alter
FIG. 4. NF-kB activation by B95.8 and CAO-LMP1 chimeras. (A)
Schematic representation of B95.8 and CAO-LMP1 chimeras generated
in this study. Solid black lines represent B95.8-LMP1 sequence and
dotted lines denote CAO-LMP1 sequence. HEK 293 cells were trans-
fected with 5 mg pSG5 or pSG5-based LMP1 wild-type and chimera
constructs in the presence of a NF-kB luciferase reporter plasmid
(kBconA-Luc) and equivalent amounts of a b-galactosidase expression
vector (CMV-b-gal). Thirty-six hours posttransfection, cells were har-
vested, and samples were analysed for LMP1 expression by immuno-
blotting (A) and NF-kB activity by reporter assays (B). Relative luciferase
alues [RLV (NF-kB)] were calculated as the ratio of luciferase vs
b-galactosidase activity and results are depicted as means 6 standard
deviation of three independent experiments.he conformation of the protein and thus the association if adapter proteins and downstream signalling path-
ays. HEK 293 cells were transiently transfected with 5
mg pSG5 or pSG5-based LMP1 wild-type and chimera
constructs in the presence of 50 ng kBconA-Luc and 50
g CMV-b-gal. Cells were harvested 36 h posttransfec-
ion and the lysates subjected to immunoblotting and
eporter assays. Immunoblot analysis demonstrated that,
s expected, B95.8/CAO-LMP1 and B95.8(45)/CAO-LMP1
ad molecular weights identical to CAO-LMP1 and CAO/
95.8-LMP1 had a molecular weight identical to B95.8-
MP1 (Fig. 4A). Luciferase reporter assays showed that
95.8/CAO behaved in a similar manner to B95.8-LMP1,
hilst the CAO/B95.8 and B95.8(45)/CAO behaved in a
imilar manner to CAO-LMP1 with respect to NF-kB
ctivation (Fig. 4B), thus implicating sequences within
he transmembrane domains as responsible for in-
reased NF-kB activation by CAO-LMP1.
AO-LMP1 has a prolonged half-life
LMP1 is similar to growth factor receptors in that it is
urned over rapidly, and pulse–chase analysis has
hown that it has a half-life of between 2 and 8 h,
epending on the cell type (Baichwal and Sugden, 1987;
ann and Thorley-Lawson, 1987; Martin and Sugden,
991a,b; Moorthy and Thorley-Lawson, 1990). Deletion
nalysis identified the amino terminus and transmem-
rane domains as important in regulating the turnover of
95.8-LMP1 (Martin and Sugden, 1991b). To determine
hether CAO-LMP1’s ability to activate higher levels of
F-kB than B95.8-LMP1 could be explained by a differ-
ence in half-life, pulse–chase analysis was performed in
HEK 293 cells transiently transfected with 5 mg pSG5-
based LMP1 constructs. Figure 5 (top) shows a repre-
sentative experiment of HEK 293 cells transiently trans-
fected with 5 mg pSG5 B95.8-LMP1 or pSG5 CAO-LMP1
with pulse–chase analysis at 0, 2, 4, 6, and 10 h. Follow-
ing autoradiography, half-life was quantified by laser
densitometry and plotted as a percentage of the original
signal (bottom). In three independent experiments,
B95.8-LMP1 was found to have a half-life of 2.9 6 0.6 h,
consistent with the half-life of B95.8-LMP1 reported in
other cell types (Baichwal and Sugden, 1987; Mann and
Thorley-Lawson, 1987; Martin and Sugden, 1991a,b).
However CAO-LMP1 was found to have an extended
half-life of 7.25 6 1.78 h. To determine the region of
CAO-LMP1 responsible for this difference in half-life,
HEK 293 cells were transiently transfected with 5 mg
SG5 B95.8/CAO (Fig. 6A), CAO/B95.8 (Fig. 6B), or
95.8(45)/CAO (Fig. 6C), and pulse–chase analysis was
erformed. In three independent experiments, B95.8/
AO had a half-life of 3.9 6 0.45 4, similar to that of
95.8-LMP1, whilst CAO/B95.8 had a half-life of 7.17 6
.26 h and B95.8(45)/CAO had a half-life of 6.95 6 1.34 h,
oth similar to that of CAO-LMP1. These results suggest
hat the transmembrane domains are responsible for
ncreased half-life of CAO-LMP1.
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282 BLAKE ET AL.DISCUSSION
Whether particular LMP1 variants contribute to EBV-
ssociated oncogenesis remains unclear, and the func-
ional significance of mutations and deletions in LMP1 is
argely unknown. This study demonstrates that the trans-
embrane domains of the NPC-derived LMP1 variant
AO confer enhanced signalling activity in transiently
ransfected epithelial cells. The region of CAO-LMP1
esponsible for this enhanced signalling also maps to
hat which prolongs the half-life of the protein, suggest-
ng that the effects of CAO-LMP1 on NF-kB and AP-1 may
be a direct result of increased protein stability. These
results are consistent with a recent study in lymphoid
cell lines (Johnson et al., 1998) but contrast with obser-
vations in stably expressing epithelial cells where, al-
though able to activate equivalent levels of NF-kB, CAO-
LMP1 is unable to substantially upregulate AP-1 (Daw-
son et al., 2000). It is an interesting paradox that,
although able to signal NF-kB and AP-1, CAO-LMP1 ap-
ears to be unable to block differentiation, induce IL-6 or
L-8 secretion, or upregulate CD54 or CD40 (Dawson et
l., 2000; Johnson et al., 1998). The chimeras generated
n this study may enable mapping of these phenomena.
Given that B95.8 and CAO-LMP1 are virtually identical
ver the CTAR1 and CTAR2 domains, it was perhaps
urprising that there should be a difference in their ability
o activate cellular signalling pathways. The major differ-
nce in the carboxyl-termini of these two variants lies in
he repeat region between CTAR1 and CTAR2 in which
FIG. 5. CAO LMP1 has a prolonged half-life. HEK 293 cells were
transiently transfected with 5mg pSG5 B95.8 or CAO-LMP1. Pulse
hase analysis was performed 24h post-transfection and cells har-
ested at time points of 0, 2, 4, 6 and 10 h. The upper panel shows a
epresentative experiment and the lower panel shows half-life quanti-
ied by densitometry and plotted as a percentage of the original signal.
n three independent experiments B95.8-LMP1 was found to have a
alf-life of 2.9 h 6 0.6, whilst CAO-LMP1 has a half-life of 7.25 h 6 1.78.here are three additional 33-bp repeats and a 30-bp beletion. The effect of these changes and whether they
ffect LMP1’s ability to engage signalling adapter mole-
ules such as TRAFs and TRADD are unknown. This
egion has recently been shown to interact with JAK3 and
ctivate STAT proteins (Gires et al., 1999), and the ability
f CAO-LMP1 to activate this pathway will be an inter-
sting area of future investigation. However, using chi-
eric molecules, this study has implicated the trans-
embrane domains of LMP1 in regulating its signalling
apacity. The role of the transmembrane domains is
onsidered predominantly structural, serving to localise
he protein in the plasma membrane and enable oligo-
erisation. However, the transmembrane domains have
lso been found to contribute to toxicity in both rodent
nd lymphoid cell lines (Hammerschmidt et al., 1989),
nd more recent work demonstrates that these regions
an inhibit cell proliferation (Kaykas and Sugden, 2000)
nd activate the Rho-like GTPase Cdc42, leading to actin
olymerisation and filopodia formation in fibroblasts
Puls et al., 1999). Further studies are in progress to
identify mechanisms by which the transmembrane do-
main of LMP1 influences these functional properties.
There has been an abundance of data in recent years
describing deletions and mutations within the carboxyl-
terminus of LMP1 in EBV-associated malignancies
(Berger et al., 1999; Chen et al., 1992; Cheung et al., 1996,
998; Chiang et al., 1999; Hu et al., 1991; Kingma et al.,
996; Knecht et al., 1993, 1995; Palefsky et al., 1996;
andvej et al., 1994; Santon et al., 1995), but few studies
ave considered sequence variation in the transmem-
rane domains. The enhanced NF-kB activation from
CAO-LMP1 is consistent with the Mediterranean NPC-
derived C15 LMP1 (Miller et al., 1998). Comparative se-
quence analysis of the transmembrane domains of
B95.8-LMP1 and the NPC-derived variants CAO and C15
identified four loci at which CAO and C15 LMP1 differed
from B95.8 but were identical to each other (residues 85,
106, 122, and 129). However, mutagenesis at these four
loci failed to identify a single residue as responsible for
CAO-LMP1’s enhanced NF-kB activation (data not
shown). Further analysis with various combinations of
these point mutants may identify the critical residues
involved in regulating signalling capacity. Similar amino
acid changes to those in the transmembrane domain of
CAO-LMP1 have also been observed in the NPC-derived
LMP1 variant 1510 (Chen et al., 1992), four NPC biopsies
Cheung et al., 1998), and three cases of hairy leukopla-
ia (Palefsky et al., 1996), and further analysis is required
o determine the significance of these changes.
The regions of LMP1 required for correct protein turn-
ver include the amino acids 322–364 (Moorthy and
horley-Lawson, 1993), and thus it has been postulated
hat the 30-bp deletion observed in many LMP1 variants
ay lead to a prolonged half-life (Sandvej et al., 1994).
his study has shown that CAO-LMP1 has a prolonged
alf-life, but this property was localised to the transmem-
rane domains. These domains of CAO-LMP1 contain
Bt
283ENHANCED SIGNALLING FROM CAO-LMP1the majority of the mutations, and one possibility is that
these mutations enable an interaction with another
membrane protein thus stabilising CAO-LMP1 in the
membrane. An alternative possibility is that these muta-
tions in CAO-LMP1 block its degradation. Recent find-
ings have implicated the ubiquitin-proteasome pathway
FIG. 6. The prolonged half-life of CAO-LMP1 is mediated through its
mg pSG5-based LMP1 constructs, and LMP1 half-life was determin
posttransfection and cells harvested at various time points. The top pa
quantified by densitometry and plotted as a percentage of the origi
95.8/CAO-LMP1. In three independent experiments, B95.8/CAO-LMP1
transfected with 5 mg pSG5 CAO/B95.8-LMP1. In three independent ex
HEK 293 cells were transiently transfected with 5 mg pSG5 B95.8(45)/C
o have a half-life of 6.95 6 1.34 h.and phosphorylation in the degradation of LMP1, with itsshort amino terminus shown to be essential for subse-
quent degradation (Aviel et al., 2000). Given the muta-
tions in the amino terminus of CAO-LMP1, it would be
interesting to investigate its ubiquitination and phosphor-
ylation and determine the mechanism by which it is
degraded. Further detailed analysis of the amino termi-
embrane domains. HEK 293 cells were transiently transfected with 5
pulse–chase analysis. Pulse–chase analysis was performed 24 h
how representative experiments and the bottom panels show half-life
nal. (A) HEK 293 cells were transiently transfected with 5 mg pSG5
nd to have a half-life of 3.9 6 0.45 h. (B) HEK 293 cells were transiently
ts, CAO/B95.8-LMP1 was found to have a half-life of 7.17 6 1.26 h. (C)
P1. In three independent experiments, B95.8(45)/CAO-LMP1 was foundtransm
ed by
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284 BLAKE ET AL.ubiquitination and phosphorylation and thereby help to
reconcile the relative contributions of the extreme amino
terminus and the transmembrane domains to the pro-
longed half-life of CAO-LMP1.
In summary, this study has implicated increased pro-
tein stability in the ability of the NPC-derived LMP1
variant CAO to activate enhanced levels of NF-kB and
P-1. Taking into account the role of these transcription
actors in oncogenesis (Ip and Davis, 1998; Rayet and
elinas, 1999), this data may have important implications
or our understanding of the enhanced transforming ca-
acity of CAO-LMP1 (Hu et al., 1993).
MATERIALS AND METHODS
NA constructs
pSG5 B95.8-LMP1 and pSG5 CAO-LMP1 have been
reviously described (Huen et al., 1995; Johnson et al.,
998). To generate a B95.8/CAO-LMP1 chimera compris-
ng the amino terminus and transmembrane domains of
95.8-LMP1 and the carboxyl-terminus of CAO-LMP1, an
rtificial KpnI site was first introduced at amino acid (aa)
92 of pSG5 B95.8-LMP1 using site-directed mutagene-
is as previously described (Eliopoulos and Young, 1998)
mutated oligonucleotide primers used were 59-GGA-
AACGACACGGTACCGAACACCACCACG-39 and its
complimentary oligo; mutated positions are underlined).
The carboxyl-terminus of B95.8-LMP1 was then removed
by digestion with BamHI and KpnI. The carboxyl-termi-
nus of CAO-LMP1 (aa 192–404) was PCR amplified using
a 59-primer with an artificial KpnI site (59-ACGACACGG-
TACCGAACACCA-39; mutated positions are underlined)
and a 39-primer with an artificial BamHI site (59-CGT-
GCGGATCCTTAGTCATAGTAG-39; mutated positions are
underlined). The PCR product was then cloned in frame
into the amino terminal/transmembrane sequences of
pSG5 B95.8-LMP1 to generate B95.8/CAO. To generate
the chimera comprising the amino terminus and trans-
membrane domains of CAO-LMP1 and the carboxyl-ter-
minus of B95.8-LMP1, site-directed mutagenesis was
used to introduce an artificial KpnI site at aa 192 of pSG5
AO-LMP1 (mutated oligonucleotide primers used were
9-GGACCACGACACGGTACCGAACACCACCACG-39 and
its complimentary oligo; mutated positions are under-
lined). The carboxyl-terminus of CAO-LMP1 was then
removed by digestion with BamHI and KpnI. The carbox-
yl-terminus of B95.8-LMP1 (aa 192–386) was isolated
from pSG5 B95.8-LMP1 containing a KpnI site at aa 192,
following digestion with KpnI and BamHI. The isolated
product was then cloned in frame into the amino termi-
nal/transmembrane sequences of pSG5 CAO-LMP1 to
generate CAO/B95.8. To generate a chimera comprising
the amino terminus and first transmembrane loop of
B95.8-LMP1 (aa 1–45) and the remainder of CAO-LMP1
(45–404), site-directed mutagenesis was used to intro-
duce an artificial KpnI site at aa 45 of both pSG5 B95.8-
LMP1 and pSG5 CAO-LMP1 (mutated oligonucleotideprimers used were 59-ATCGTTATGGGTACCTGGACTG-
GAGGAGC-39 and its complimentary oligo; mutated po-
sitions are underlined). Amino acids 45–386 of B95.8-
LMP1 were then removed by digestion with BamHI and
KpnI, and a BamHI/KpnI fragment corresponding to aa
45–404 of CAO-LMP1 was then cloned in frame into
pSG5 B95.8-LMP1 (1–44) to generate B95.8(45)/CAO. The
sequences of these hybrid constructs were verified by
DNA sequencing, which was performed on an ABI
Prism377 DNA Sequencer using the Big Dye DNA Se-
quencing Kit (Perkin–Elmer).
Cell culture, transfections, and reporter assays
Human embryonic kidney (HEK) 293 cells were grown
in DMEM supplemented with 10% foetal calf serum, 2
mM glutamine, 1000 U/ml penicillin, and 1 mg/ml strep-
tomycin. SV40-transformed human keratinocytes (SVK)
were grown in Joclics supplemented with 8% foetal calf
serum, 2 mM glutamine, 1000 U/ml penicillin, 1 mg/ml
streptomycin, and 0.4 mg/ml hydrocortisone. For tran-
ient transfection of HEK 293 cells, 1 3 106 cells were
plated out in a 25-cm2 flask and transfected the following
day using a standard calcium phosphate technique. For
transient transfection of SVK cells, 1.53 106 cells were
plated out in a 25-cm2 flask and transfected the following
day using a modified DEAE-dextran method (Gonzalez
and Joly, 1995).
SDS–PAGE and immunoblotting
Immunoblotting was performed using the and the pro-
teins transferred to a nitrocellulose membrane. Follow-
ing incubation in blocking buffer (5% skimmed milk in
0.1% PBS-Tween) for 1 h at room temperature, the mem-
brane was incubated overnight at 4°C with agitation in
CS.1–4 monoclonal antibody. The membrane washed for
30 min in 0.1% PBS-Tween and incubated for 1 h at room
temperature with agitation in HRP-conjugated secondary
antibody. The membrane was washed in PBS-Tween 20
for $1 h with several changes of buffer and the proteins
detected by enhanced chemiluminescence (ECL; Amer-
sham Pharmacia Biotech).
Electrophoretic mobility shift assays
EMSA probes were prepared by first annealing com-
plementary synthetic oligonucleotides at 95°C for 5 min
in 13 buffer B (Boehringer Mannheim). The probes were
end-labeled in a reaction containing 3 mCi [g-32P]ATP, 1
pmol annealed probe, 5 ml 103 polynucleotide kinase
(PNK) buffer and 2 ml PNK (Boehringer Mannheim) for 1 h
at 37°C. The probe was then isolated using the Qiaquick-
Nucleotide Removal Kit (Qiagen) according to the man-
ufacturer’s instructions. To prepare nuclear extracts,
cells were washed twice in PBS and resuspended in 100
ml buffer A (10 mM HEPES pH 7.9, 2% v/v N-P40, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM DTT, 100 mg/ml leupeptin, 0.5
mM PMSF, and 1 mM benzamidine), which lyses the cell
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285ENHANCED SIGNALLING FROM CAO-LMP1membrane. Cell nuclei were pelleted by centrifugation at
13,000 rpm for 10 s and the nuclei lysed in 100 ml buffer
C (20 mM HEPES pH 7.9, 25% v/v glycerol, 1.5 mM MgCl2,
0.42 M NaCl, 0.2 mM EDTA, 0.5 mM DTT, 100 mg/ml
leupeptin, 0.5 mM PMSF, and 1 mM benzamidine) by
incubation on ice for 30 min. Nuclear debris was pelleted
by centrifugation at 13,000 rpm at 4°C for 5 min, and
nuclear protein concentration was determined using the
Biorad protein assay. The reaction containing 4 mg nu-
lear extract, 1 mg poly dIdC (Pharmacia), 5 mM DTT, and
.1 ng probe was incubated on ice for 30 min. The
eaction was resolved by electrophoresis on a 5% poly-
crylamide gel in 0.53 TBE buffer. The gel was dried and
xposed to X-ray film. The probes used in this study to
ssess NF-kB and AP-1 binding were described previ-
ously (Eliopoulos et al., 1997; Eliopoulos and Young,
998).
ulse–chase analysis and immunoprecipitation
Transiently transfected cells were incubated in methi-
nine/cysteine-free DMEM for 30 min. This media was
hen replaced with met/cys-free DMEM containing 0.2
Ci/ml [35S]methionine/cysteine protein labelling mix
(NEN) and the cells incubated at 37°C for 1 h (pulse).
Following the incubation, the cells were washed three
times with methionine/cysteine-free DMEM, complete
media was added and the cells were returned to 37°C.
The cells were harvested at various time points (chase).
Cells were harvested and lysed in RIPA buffer (50 mM
Tris pH 8, 150 mM NaCl, 1% v/v N-P40, 0.5% w/v deoxy-
cholate, 0.1% w/v SDS, 5 mg/ml leupeptin, 2 mg/ml apro-
tinin, 0.5 mM sodium orthovanadate, and 1 mM PMSF)
on ice for 30 min, and the cell debris pelleted by centrif-
ugation at 13,000 rpm for 5 min at 4°C. Protein concen-
tration was determined using the Biorad protein assay.
Two hundred microgams protein was precleared with 10
ml of 50% v/v sepharose–protein G at 4°C with rotation
for 1 h. The CS.1 monoclonal antibody (Rowe et al., 1987)
was added to the pre-cleared supernatants and the sam-
ples incubated at 4°C with rotation for 2 h. Twenty-five
microliters of 50% v/v protein G–sepharose beads were
added and the samples rotated at 4°C for 2 h. The beads
were pelleted by centrifugation and washed four times
with RIPA buffer. Following the final wash, the beads
were drained with a fine-gauge Hamilton syringe, 50 ml
SB added, and the samples boiled for 4 min. The
amples were then electrophoresed and the gel stained
ith 0.1% w/v Coomassie Blue stain for 30 min and
estained in Destain solution I (45% v/v methanol, 10%
/v glacial acetic acid) for 1 h. The gel was rehydrated in
estain solution II (5% v/v methanol, 5% v/v glacial acetic
cid) for 1 h, incubated in Amplify (Amersham Pharmacia
iotech) for 15 min to enhance the signal and dried.
utoradiography and densitometry were used to quanti-ate the assays.ACKNOWLEDGMENTS
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